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Neurotoxic organophosphorus compounds (OPs), which are used as pesticides and chemical warfare
agents lead to more than 700,000 intoxications worldwide every year. The main target of OPs is the inhi-
bition of acetylcholinesterase (AChE), an enzyme necessary for the control of the neurotransmitter ace-
tylcholine (ACh). The control of ACh function is performed by its hydrolysis with AChE, a process that
can be completely interrupted by inhibition of the enzyme by phosphylation with OPs. Compounds used
for reactivation of the phosphylated AChE are cationic oximes, which usually possess low membrane and
hematoencephalic barrier permeation. Neutral oximes possess a better capacity for hematoencephalic
barrier permeation.
NMR spectroscopy is a very conﬁdent method for monitoring the inhibition and reactivation of
enzymes, different from the Ellman test, which is the common method for evaluation of inhibition and
reactivation of AChE. In this work 1H NMR was used to test the effect of neutral oximes on inhibition
of AChE and reactivation of AChE inhibited with ethyl-paraoxon. The results conﬁrmed that NMR is a very
efﬁcient method for monitoring the action of AChE, showing that neutral oximes, which display a signif-
icant AChE inhibition activity, are potential drugs for Alzheimer disease. The NMR method showed that a
neutral oxime, previously indicated by the Ellman test as better in vitro reactivator of AChE inhibited
with paraoxon than pralidoxime (2-PAM), was much less efﬁcient than 2-PAM, conﬁrming that NMR is
a better method than the Ellman test.
 2013 Published by Elsevier Ltd.1. Introduction
Organophosphorus compounds (OPs) are important molecules
used as pesticides, covering about 40% of this market.1 Unfortu-
nately, the inadequate use of organophosphorus pesticides causes
intoxication in humans and animals, several suicides and consider-
able environmental damages.2–5 According to the World Health
Organization (WHO), the OPs cause about 3 million intoxications
and 200,000 deaths in the whole world every year.6 In fact, the bio-
logical effects of OPs depend on the interaction time, concentration
and type of OP to which the victim was exposed.7,8 The toxicity of
OPs varies signiﬁcantly depending on their structures, and the
most dangerous are the chemical warfare agents.9,10 The OPs tox-
icity differences are related with their structural characteristics,
such as the type of functional groups bound to the phosphorus
atom.9,10
The main action of neurotoxic OPs is the inhibition of acetylcho-
linesterase (AChE).11–13 The function of this enzyme is the controlof nerve impulse transition by hydrolysis of the neurotransmitter
acetylcholine (ACh), which is liberated on the neuronal synapse
at the autonomous and central nervous system, as well as at neu-
romuscular junctions.14–17 The hydrolysis of ACh by human AChE
happens at the enzyme’s active site, with participation of the ami-
no acid residues Ser203, Glu334 and His447.9,18 The inhibition of
AChE by OPs occurs by phosphylation of Ser203, which is the ami-
no acid directly involved in the ACh hydrolysis process, leading to
cholinergic crisis and death.18,19
The reactivation of the AChE function in patients intoxicated
with OPs is actually performed by administration of cationic pyrid-
inic oximes.10,20–23 These oximes act by dephosphylation of
Ser203.18,24–32 Nowadays there are many reports of new oximes
with good efﬁciency as AChE reactivators.33–48 However, there
are still several problems with this type of drugs. For example,
most of these oximes are not good hematoencephalic barrier perm-
eators, thus leading to restrictions on their brain activites.41,49 Also,
it has not been discovered a single oxime that is effective to reac-
tivate AChE inhibited with any type of neurotoxic OP.10,20,23
The treatment of Alzheimer disease (AD), which is an important
brain problem that affects about 30 million people in the whole
world, is also related to AChE activity.50 AD usually leads to
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a serious decrease of the number of neural transmitters, like ACh.
Therefore, competitive inhibitors of AChE are used for the treat-
ment of AD patients, because its inhibition leads to brain concen-
tration increase of ACh, re-establishing the neuron functions.51
It has been shown that neutral oximes, which normally have a
better hematoencephalic barrier permeation, display a potential
to function as inhibitors of AChE or reactivators of phosphylated
AChE.41,49–52
The physical–chemical phenomena related to ligand-receptor
intermolecular interactions are fundamental for understanding
biological processes. In this context, nuclear magnetic resonance
spectroscopy (NMR) is one of the most powerful techniques for li-
gand–protein interaction studies, being an efﬁcient method to
determine and quantify intermolecular interactions.53–57 NMR is
also a very conﬁdent technique for the detection and identiﬁcation
of different compounds, thus making it a very secure monitoring
method for kinetics studies of inhibition and reactivation of
enzymes.58
Enzyme inhibition studies are normally conducted using UV–
visible spectroscopy methods.59 However, in some cases, these
methods require the use of a second enzyme to transform the
substrate of the tested enzyme into a secondary product with a
very different kmax. In this case, the tested enzyme inhibitor could
also interact with the second enzyme, leading to wrong results.
Also, some UV–visible methods require the use of a different sub-
strate to test the enzyme. For example, the Ellman test needs the
use of acetyl thiocholine instead of acetylcholine (ACh) as sub-
strate for acetylcholinesterase (AChE).60 Despite the fact that
acetyl thiocholine functions well as a substrate for AChE, not
using ACh as substrate could lead to variations on the inhibition
and reactivations tests. A good alternative to UV–visible methods
is the use of Nuclear Magnetic Resonance (NMR). The disadvan-
tages of NMR in comparison with UV–visible methods are the
fact that the former is a less sensitive method, requiring the
use of relatively higher concentrations and longer testing times.
The main advantage of NMR is its precision, especially on the
deﬁnitive detection and differentiation of enzyme substrates,
products and inhibitors. For this reason, enzyme inhibition tests
with NMR do not need substrate exchange or the use of another
enzyme to modify the product.
The objective of this work was to use 1H NMR spectroscopy to
study the capacity of neutral oximes as inhibitors of Electrophorus
electricus (EeAChE) and reactivators of EeAChE inhibited by parao-
xon (1), in comparison with 2-PAM (2) (Fig. 1). These two topics
were selected to determine the efﬁciency of NMR in both methods.
In this work, despite 2-PAM not being the most effective reacti-
vator for paraoxon-inhibited AChE, it was selected as positive stan-
dard compound because, in comparison with the other effective
cationic oximes, its structure is the most similar to the tested neu-
tral oximes, allowing better comparison of the results due to differ-Figure 1. AChE inhibitor and oximes tested as inhibitors and reactivators of EeAChE: Par
benzaldoxime (5), 4-ﬂuor-benzaldoxime (6), 4-chloro-benzaldoxime (7) and 4-nitro-benences on molecular properties but less with molecular structure
differences.
Several enzymes can be used for kinetics, inhibition and reacti-
vation studies of AChE.61 The active site of EeAChE is basically iden-
tical with the one of human acetylcholinesterase (HuAChE).62 The
selection of EeAChE for this work was based on its better reactiva-
tion by pralidoxime when inhibited with paraoxon when com-
pared with HuAChE. This difference is not based on the amino
acid sequence of the active sites but on non-reactivation process,
denaturation or aging, of the human enzyme.63
2. Materials and methods
2.1. Material solutions
2.1.1. Phosphate buffer pH 7.4
All monitoring processes by NMR were performed using phos-
phate buffer at pH 7.4 in 98% D2O as solvent. The buffer solution
was prepared at 0.01 M concentration with dry sodium mono-ba-
sic phosphate (NaH2PO4) and dry sodium di-basic phosphate
(Na2HPO4).
2.1.2. EeAChE solution
In a 5.00 mL volumetric balloon, 710 lL of Electrophorus electri-
cus AChE (100 UN/mL, quaternary form, CAS number 0009000811,
C2888 from Sigma Aldrich) and 0.5 mg of bovine serum albumin
(BSA, A2153) were dissolved in 4.00 mL of phosphate buffer (pH
7.4) and the solution volume was adjusted to 5.00 mL. The solution
was kept in storage at 4 C, with a EeAChE concentration of
0.33 nM.
2.1.3. Solution of substrate: acetylcholine (ACh)
In a 10.00 mL volumetric balloon, 546 mg of ACh (Sigma–
Aldrich) were dissolved in 8.00 mL of phosphate buffer (pH 7.4)
and the solution volume was adjusted to 10.00 mL, leading to a
ACh concentration of 0.30 M.
2.1.4. Oximes solutions
Each oxime solution was prepared in a 1.00 mL volumetric bal-
loon using 12.0 lmol of the oxime, 125 lL of DMSO-d6 and the
necessary amount of phosphate buffer (pH 7.4) to complete the
volume. The ﬁnal concentration of each oxime was 12.0 mM.
2.1.5. Ethyl-paraoxon solution
The basic solution of ethyl-paraoxon was prepared by dissolv-
ing 100 lL of pure-ethyl-paraoxon (127.4 lg) (density 1.274 g/
mL) in a 50.00 mL volumetric balloon, using distilled water as sol-
vent. 2.0 lL of the basic solution ware poured into a 5.00 mL volu-
metric balloon and the volume completed with phosphate buffer
(pH 7.4), leading to a ﬁnal solution of 3.70 nM concentration,
which was used for inhibition of EeAChE.aoxon (1), pralidoxime (2), thiophene-2-aldoxime (3), 4-methoxy-benzaldoxime (4),
zaldoxime (8).
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All NMR experiments were performed at 20.0 ± 0.1 C in the
Varian Inova 500 MHz spectrometer of the LNBio (National Biosci-
ence Laboratory) in Campinas/SP (Brazil). The samples were pre-
pared in 5 mm NMR tubes using phosphate buffer in D2O (pH
7.4) as solvent. All samples were prepared exactly 1 min before
their introductions into the magnet, and the lock and shimming
process was carried in all samples during 4 min, in order to have
exactly the same processing time in all experiments. The number
of transients for each spectrum was 16 and the acquisition time
was 3.75 s for each transient.
2.2.1. NMR monitoring of EeAChE inhibition by neutral oximes
Monitoring ACh hydrolysis by EeAChE was performed with
NMR by integration of the singlet signal of the ACh methyl group
at 2.24 ppm and of the produced acetic acid at 2.16 ppm. The signal
intensity in all tests was calculated by integration of a 0.3 ppm
zone centralized on each methyl signal.
In each case, the different solution components were added in
the following order: ﬁrstly 2.00 lL of the basic solution of EeAChE,
followed by 5.00 lL of the respective oxime solution, then 5.00 lL
of ACh solution and the necessary volume of phosphate buffer to
adjust the total solution volume to 600 lL. Each experiment was
performed with the following concentrations: 2.5 mM of ACh,
1.09 pM of EeAChE and 0.1 mM of oxime. The hydrolysis process
was monitored by collection of 1H NMR spectra in intervals of
5 min. Each spectrum was obtained using 30 pulses and 16 scans,
with d1 of 0.5 s and at 20 C (NMR room temperature). The process
was also executed with EeAChE and ACh without oximes, in order
to use these results as the positive comparative data. All experi-
ments were executed in duplicate.
2.2.2. Inhibition of EeAChE with ethyl-paraoxon
AChE inhibition was ﬁrst conducted by treatment of 2.0 lL of
the AChE solution (0.33 nM) with 1.5 lL of the ethylparaoxon
(diethyl-4-nitrophenyl phosphate) solution (3.70 nM) for 1 h at
25 C. After 1 h, the inhibited enzyme solution was mixed with
5.0 lL of ACh solution and monitored by NMR for 60 min, indicat-
ing that ACh was completely not hydrolyzed, conﬁrming the AChE
inhibition. Monitoring the reactivation process of the inhibited
AChE was conducted with the same conditions used for the inhibi-
tion studies of this enzyme (Section 2.2.1), but 5.00 lL of the
respective oxime solution were added before adjusting the ﬁnal
volume to 600 lL. Pralidoxime (2-PAM) was used as positive
control.
2.2.3. NMR monitoring neutral oximes reactivation of EeAChE
inhibited with paraoxon
To analyze the process of reactivation of EeAChE inhibited with
ethyl-paraoxon by NMR, it was used the previously described pro-
cedure applied for the oxime inhibition monitoring (Section 2.2.1),
with the pure EeAChE fraction (2.0 lL) replaced by the ethyl-
paraoxon inhibited EeAChE solution (2.0 lL) on the same
concentration.
2.3. Synthesis of oximes
All used oximes, which are known compounds, were prepared
by reaction of the respective aldehydes (2.0 mmol) with hydroxyl-
amine hydrochloride (4.0 mmol) in a 50 mL round bottom ﬂask,
using a mixture of 3.0 mL of water and 10 mL of 95% ethanol as sol-
vent.41 The reaction mixture was kept under stirring at 25 C for
24 h. The precipitated products were separated by ﬁltration and
recrystallized from methanol, leading to the pure oximes with
yields from 60% to 85%. The structure and purity of each preparedoxime was conﬁrmed by 1H and 13C NMR spectra (See Supplemen-
tary Material).
2.4. Molecular modeling
All oximes structures were optimized on Intel dual 2.66 GHz
processor with 2048 Mb RAM using the Spartan06 package with
the functional density (DFT) B3LYP method and the 6-311++G⁄⁄ ba-
sis set. The obtained molecular properties were relative energy (kJ/
mol), molecular mass (atomic units – amu), molecular area (MA),
PSA (polarization surface area), LogP and dipole moment (Debye).3. Results and discussion
1H NMR spectroscopy was chosen to monitor the inhibition and
reactivation of AChE in order to develop a simple and more effec-
tive method, which could be applied on further studies for the
development of potential compounds for treatment of Alzheimer
disease (AD) and defense agents against organophosphorus chem-
ical weapons. Inhibition and reactivation o AChE were executed in
order to determine the efﬁciency of NMR in both methods. The
other motive for working in these two topics is that development
of AChE inhibitors for Alzheimer disease and reactivators of AChE
inhibited by organophosphorus compounds, are two important
topics for health problems.
The fact that cationic oximes, which are usually pyridine deriv-
atives, are used as reactivators of AChE conﬁrms that they interact
with AChE active site, suggesting that they could also act as AChE
competitive inhibitors. One of the problems of AD is the small pro-
duction of the neurotransmissor acetylcholine (ACh) on the pa-
tients. For this reason, AChE inhibitors are used to increase ACh
concentration, resulting in better brain performance.64,65 Accord-
ingly, oximes could also have potential for the treatment of AD,
especially the neutral ones, which display a better permeation
through the hematoencephalic barrier than the cationic oximes.
Some simple neutral oximes were reported as potential reacti-
vators of human AChE inhibited with paraoxon.41 Some of these
compounds, shown in Figure 1, were selected for NMR testing in
this work, in order to compare this method with the Ellman test
and to evaluate the effect of the para-substituent of benzaldoximes
(4–8) on their capacity to inhibit or reactivate AChE. For example,
thiophene-2-aldoxime (3) was selected because, when tested as
human AChE reactivator using the Ellman test, it gave better re-
sults (93% reactivation) than 2-PAM (83% reactivation).41 As the
positive active reference compound we selected pralidoxime (2),
which is the simplest commercial cationic oxime with reasonable
AChE reactivating capacity, but usually insufﬁcient against very
toxic organophosphorus warfare agents.66 There are other cationic
oximes with better reactivation capacity than pralidoxime,67 but
this compound was selected as control for two reasons. The ﬁrst
motive for selecting 2-PAM is its structural similarity to the tested
neutral oximes, a condition that allows a better comparison of the
obtained results. The second motive is the comparison of obtained
NMR results with the Ellman test previously executed with these
compounds, a process that was also executed using 2-PAM as po-
sitive control.41 Also, because the Ellman test was executed with
AChE inhibited with paraoxon, this compound was selected as
organophosphorus inhibitor in this work.
3.1. Inhibition of EeAChE
The main problem of monitoring enzyme activity by NMR is the
necessity of manipulation of the samples after mixing all compo-
nents in a 5 mm NMR tube. For this reason, the addition of the en-
zyme substrate needs to be performed as the last sample
Figure 3. Example of the methyl signal variation of acetylcholine (left signal) and
acetate (right signal) under the effect of EeAChE in the presence of benzaldoxime
(5).
Figure 4. Comparison of the methyl signal intensity of acetylcholine (ACh) with
acetic acid (AcOH) during the EeAChE action in the presence of benzaldoxime (5).
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hydrolysis process. Because AChE is a very fast enzyme, with a
turnover number of 7.4  105 molecules/min,68 the substrate could
be completely hydrolyzed in few minutes, preventing NMR moni-
toring. To solve that problem, the concentration of the enzyme
must be very low, in order to make it act during a much longer
time. So, AChE with a concentration of 1.1 pM was used, leading
to a slow hydrolysis process that could be monitored by 1H NMR
during several minutes.
In order to avoid differences among the experiments, the
NMR process was followed using exactly the same sample prep-
aration procedure and NMR sample lock and shimming process-
ing time. Therefore, all samples were prepared directly in the
5 mm NM tube during 1 min, with the introduction of ACh as
last step. Also, the introduction of the sample in the NMR mag-
net, followed by locking and shimming processes, was conducted
in exactly 4.0 min for all samples. This procedure was necessary
in order to establish appropriate conditions to compare the re-
sults obtained in all experiments, which were carried out in
duplicate. In this form, analyses of all samples were started ex-
actly 4.0 min after the addition of ACh. Each experiment required
16 scans and an acquisition time of 3.75 s, leading to a total time
of 1.0 min for each spectrum. That procedure conﬁrmed the ini-
tiation of each spectrum after 5.0 min in all experiments. The
hydrolysis of acetylcholine by AChE initially leads to formation
of choline (Ch) and acetylated AChE on Ser203, which is then
transformed by water to AChE and acetic acid (AcOH), as shown
in Figure 2. The complete hydrolysis process was monitored by
integration of the methyl signals of the ACh acetyl group (d
2.24), which decreases with time, and of acetate (d 2.16), which
increases with time.
The 1H NMR spectra of methyl groups of acetylcholine (ACh,
left signal, d 2.24) and acetate (AcOH, right signal, d 2.16) along
the EeAChE reaction time in the presence of benzaldoxime (5)
is shown in Figure 3. When the integration of each signal is
determined using the same spectral width it can be observed,
as shown in Figure 4, that the two methyl signals are in direct
correlation, indicating that these data can be correctly used to
monitor enzyme kinetics. In order to obtain the data for Figure
4 at time zero, it was necessary to obtain the spectrum of pure
ACh at 2.5 mM concentration without the presence of AChE,
while the other spectra with reaction time different from zero
were determined in the presence of EeAChE at 1.1 pM
concentration.
The determination of all signal intensities was accomplished by
using an integration width of 0.3 ppm centered on each signal, and
these data was correlated with the ACh and Ac concentrations. In
Figure 5 it is shown the variation of the concentration of ACh with
time in the presence of pure AChE and also in the presence of all
oximes tested in this work as potential inhibitors.
Figure 5 shows that thiophene-2-aldoxime (3) is the best inhib-
itor of all tested oximes, including 2-PAM (2). Interestingly, 2-PAMFigure 2. Hydrolysis of acetylcholine (ACh) by acetylcholinesterase (AChEpossesses a AChE inhibition capacity similar to benzaldoxime (5),
and can be observed that the neutral oximes with a strong electron
extractor (NO2, 8) or a strong electron donator group (OMe, 4) at
the para position of the aromatic ring are very inefﬁcient AChE
inhibitors. The results with compounds 4 and 8 suggest that) and chemical shifts of the methyl groups used for NMR monitoring.
Table 1
Molecular Properties of 2-PAM and the neutral oximes obtained by Molecular Modeling (B3LYP, 6-311++G⁄⁄)
4- 83
N
OH
R
S
N
OHN
N
OH
Me 2
Oxime R MM (amu) MA (Å2) PSA (Å2) DM (D) LogP DE (au) AI (%)
2 — 136.17 173.27 20.25 2.53 2.3171 0.406 34
3 — 127.17 142.93 32.96 1.07 0.4064 0.560 61
4 OCH3 151.17 182.31 39.32 2.92 2.0427 0.575 4
5 H 121.14 152.84 32.65 1.02 2.1691 0.570 37
6 F 138.14 163.60 19.84 2.15 2.3272 0.567 1
7 Cl 154.60 173.56 19.83 2.38 2.7273 0.563 22
8 NO2 166.14 177.98 71.14 5.14 2.2030 0.539 0
MM =molecular mass in atomic units (amu), MA = molecular area, PSA = polarization surface area, DM = dipole moment in Debye (D), DE = ERNOH–ERNO (atomic units, au),
AI = AChE inhibition in 30 min (%).
Figure 5. Variation of the concentration of ACh (lM) with time monitored by 1H NMR through integration of the methyl signal of the acetyl group (d 2.24). The experiment
was conducted with pure AChE (black), and with the presence of oximes: pralidoxime (red), thiophene-2-aldoxime (blue), benzaldoxime (violet), 4-methoxy-benzaldoxime
(magenta), 4-nitro-benzaldoxime (orange), 4-chloro-benzaldoxime (pink) and 4-ﬂuor-benzaldoxime (green).
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On the other hand, the comparison between the ﬂuorinated and
chlorinated oximes (6 and 7, respectively) shows that oxime 7 is
a much better AChE inhibitor than 6.
In an attempt to discover which molecular properties are re-
lated to the oximes AChE inhibition capacity, we carried out a
simple molecular modeling study of their structures and proper-
ties. Moreover, since neutral oximes could be used as drugs for
AD, their structural properties could also be related to their
capacity for permeation of the hematoencephalic barrier (or
blood–brain barrier, BBB), a characteristic we want to favor. In
general terms, molecules with molecular mass (MM) lower that
450 Da, polarization surface area (PSA) lower than 140 Å2 (with
even better performance when the PSA is lower than that
60 Å2) and a controlled hydrophilicity, would be better BBB
permeators.69 The comparison of these properties obtained bymolecular modeling analysis indicates that cationic and neutral
oximes possess appropriate molecular mass and PSA; however,
cationic oximes, which are salts, are more hydrophilic than neu-
tral oximes. These results are shown in Table 1 for pralidoxime
(2-PAM, 2) and the neutral oximes (3–9), and compared with
their percentage of AChE inhibition during a period of 30 min.
The acidities of the oximes were estimated using the energy dif-
ference (DE) between their neutral and anionic forms. Oximes
with the lowest values of DE are the most acidic ones.
These results show that none of the calculated parameters dis-
plays a good correlation with AChE inhibitory capacity. The best
correlation between the inhibition capacity (%) and the calculated
parameters occurs with MA (R2 = 0,60), Log P (R2 = 0.53), DM
(R2 = 0,51) and MM (R2 = 0,49), but none of these correlations is
satisfactory. Considering the PSA data, it can be observed that there
is no correlation between the PSA values and the AChE inhibitory
Figure 6. Graphic of the variation of ACh concentration in the presence of EeAChE
inhibited with paraoxon with the presence of the oximes. Pralidoxime (red),
thiophene-2-aldoxime (green), 4-methoxy-benzaldoxime (black), 4-nitro-ben-
zaldoxime (blue), 4-ﬂour-benzaldoxime (pink), 4-chloro-benzaldoxime (light blue)
and benzaldoxime (brown).
Table 2
Percentage of reactivation of EeAChE inhibited with paraoxon by the tested oximes in
85 min
Oxime EaAChE–paraoxon
reactivation (%)
Oxime EaAChE–paraoxon
reactivation (%)
2 97.40 6 4.04
3 8.02 7 4.42
4 7.60 8 6.61
5 10.00
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(R2 = 0.04).
Since 2-PAMwas the only cationic oxime tested, in order to bet-
ter understand the properties of the neutral oximes, we extracted
the data of 2-PAM from the correlation process. When 2-PAM data
are extracted, the only important improvement on the correlation
of AChE inhibition capacity was with MA, which increases to
R2 = 0.74, indicating that molecular area is somehow related to
AChE inhibition efﬁciency of neutral oximes. Aside from that, some
other observations are important. For example, in the case of neu-
tral oximes, the ones that possess dipole moment close to 1.0 D are
the best inhibitors (3 and 5). The other observation is that when
the dipole moment increases the neutral oximes are less effective
AChE inhibitors. It can be observed that 4-nitro-benzaldoxime
(8), with the highest MD (5.14), is the least effective neutral oxime
(0%). The only different result is for the 4-ﬂuor-benzaldoxime,
which is a very ineffective AChE inhibitor (1%), but displays a di-
pole moment of 2.15 D, lower than oximes 7 (2.38 D) and 4
(2.92 D), which are medium (22%) and low (4%) AChE inhibitors,
respectively. Pralidoxime possesses a medium DM value (2.53 D)
and a medium inhibitory capacity (34%), very similar to ben-
zaldoxime (5, 37%), which has a much lower DM value (1.02 D).
The results suggest that the behavior of cationic oximes is different
from neutral oximes.
The Log P values, without the 2-PAM data, display R2 = 0.53 on
correlation with AChE inhibition percentage, indicating that there
is not good correlation of samples solubility with their AChE inhib-
itory activity. Independently, the most effective AChE inhibitor,
thiophene-2-aldoxime (3), displays de lowest Log P value
(0.4064), being the neutral oxime most soluble in water. The sec-
ond better AChE inhibitor, benzaldoxime (5), which Log P, even dis-
playing the second lowest Log P of the neutral oximes (2.1691), is
very similar in solubility to the other tested compounds, especially
to 4-nitro-benzaldoxime, which is the worst AChE inhibitor of all.
On the other hand, the Log P of 2-PAM reported in the literature,70
is 2.31, being the most soluble of all the tested compounds, even
much more than thiophene-2-aldoxime. These results conclude
that the oximes solubility in water does not display correlation
with AChE inhibition. The good point on the reported Log P values
of the neutral oximes, in comparison with 2-PAM, is an indication
of their potential better capacity for BBB permeation than the cat-
ionic oximes.
On the other hand, the fact that the neutral oximes with the
most effective AChE inhibition capacities are 2-thiophenyl oxime
and benzaldoxime, which possess the lowest molecular mass and
the lowest molecular area, indicates that these parameters have
some impact on AChE inhibition.
3.2. Reactivation of EeAChE inhibited with paraoxon
For monitoring the capacity of neutral oximes as EeAChE reac-
tivators it was necessary to inhibit the enzyme without using an
excess of paraoxon. Accordingly, there was used the appropriate
volume (0.5 lL) of the paraoxon solution (3.33 mM) to inhibit
4.0 lL of the EeAChE solution (0.33 nM).
The inhibition was performed during 60 min. To conﬁrm the
complete EeAChE inhibition, 5.00 lL of the ACh solution were
added to the inhibited enzyme and the solution was monitored
by 1H NMR for 85 min, without any variation of ACh concentra-
tion. This solution was then mixed with 5.00 lL of pralidoxime
solution and monitored by NMR, showing an effective hydrolysis
of ACh. To conﬁrm that pralidoxime did not hydrolyze ACh, a
mixture of ACh and pralidoxime without EeAChE was also mon-
itored, showing that the concentration of ACh did not decrease
during 85 min in the presence of pralidoxime. This procedure
was repeated with all neutral oximes, showing that none of themwas an effective EeAChE–Paraoxon reactivator. The results are
shown in Figure 6.
The results are shown in Table 2, where it is evident that
the studied neutral oximes are poor EeAChE–paraoxon reactiva-
tors, when compared to pralidoxime. In fact, all neutral oximes
displayed a very similar reactivation capacity, with ben-
zaldoxime being the most effective one, followed by thio-
phene-2-aldoxime.
From the molecular modeling data of Table1, it is clear that pra-
lidoxime is the most acidic oxime, displaying a much lower DE va-
lue than all neutral oximes, which are very weak reactivators. This
analysis indicates that oximes acidity is an important factor for
their potential effect as AChE reactivators.
In order to compare the reactivation capacity of the two best
neutral oximes, benzaldoxime (4) and thiophene-2-aldoxime (3),
the experiment was repeated with these oximes and monitored
by NMR during 6 h. These results are shown in Figure 7.
Numerically, the results of Figure 7 indicate that the percentage
of EeAChE reactivated by benzaldoxime during 375 min corre-
sponds to 58.6%, while for 2-thiophenyl oxime it is 15.5%. These re-
sults conﬁrm that neutral oximes have some potential to act as
reactivators of AChE inhibited by neurotoxic organophosphorus
compounds, a process that certainly needs to be very much im-
proved in order to obtain new neutral oximes as effective agents
for defense against chemical weapons.
These NMR results are opposite to the data obtained with neu-
tral oximes using the Ellman test in a previously published arti-
cle.41 The data reported with the Ellman test indicated
thiophene-2-aldoxime (3) as a better reactivator of AChE (93%)
Figure 7. Reactivation of EeAChE–paraoxon with thiophene-2-aldoxime (green)
and benzaldoxime (brown) during 6 h.
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much more effective (97.4%) than compound 3 (8.0%).
4. Conclusions
The obtained results of AChE inhibition indicates that neutral
oximes (which possess a better capacity to permeate the hemato-
encephalic barrier than cationic oximes) with small aromatic rings
(low molecular mass and molecular surface) are effective AChE
inhibitors. These compounds have potential for the treatment of
Alzheimer disease by improving the concentration of the neuro-
transmissor acetylcholine in the patients.
Our results show that 2-PAM is only the second best EeAChE
inhibitor, indicating that its cationic form, despite being effective
for its interaction with the active site, is not the most important
characteristic for inhibition of the enzyme. These results suggest
that the presence of neutral, small and unsubstituted aromatic
rings is an important factor for AChE inhibition.
The experiments of reactivation of AChE inhibited with parao-
xon showed that pralidoxime is more effective than all neutral oxi-
mes tested, probably due to its greater acidity, that allows an easier
formation of its anionic form inside the active site of the phosphy-
lated AChE. The anionic form of oximes is necessary to perform the
effective nucleophilic attack on the phosphate group linked to
Ser203 in the enzyme active site.
Despite the low AChE reactivation capacity shown by neutral
oximes, our experiments conﬁrmed that some of these compounds
could reactivate more than 50% of the inhibited enzyme in 6 h.
These results indicate that structural variation on neutral oximes,
especially looking for more acidic compounds, could lead to the
development of new AChE reactivators with better permeability
of the hematoencephalic barrier, a characteristic that is important
to improve the efﬁciency of antidotes against intoxication with
organophosphorus compounds.
The obtained information of this work can be used for design of
new AChE inhibitors and reactivators, however using other acety-
lcholinesterases, pesticides or nerve agents, the tested results
could be different. For example, if EeAChE is inhibited by another
organophosphorus compound, it is possible that pralidoxime could
display a lower effectiveness, while one of the inactive neutral oxi-
mes could increase its reactivation capacity. In the future it would
be especially important to discover general AChE inhibitors and
reactivators.The Ellman test certainly works quite well for many
experiments, leading to real results. However, because this test
uses acetyl thiocholine instead of ACh as substrate in the presence
of 5-(3-carboxy-4-nitrophenyl)disulfanyl-2-nitrobenzoic acid
(DTNB) and is based on UV–visible spectroscopy, it could lead to
wrong results in some cases. In this test, acetyl thiocholine is
hydrolyzed to thiocholine, which reacts with DTNB to produce 5-
mercapto-2-nitrobenzoic acid, a yellow product detected by UV–
visible spectroscopy. So, if some enzyme inhibitors or reactivators
display a kmax similar to 5-mercapto-2-nitrobenzoic acid, the Ell-
man test is ﬂawed. Also, despite acetyl thiocholine being a substrate
of AChE, its difference to ACh could lead to different results. For
these reasons, the use of the NMR method is very appropriate.
In this work it was shown that NMR is a very effective and sim-
ple method to study and monitor inhibition and reactivation pro-
cesses related to acetylcholinesterase. We believe NMR is better
than Ellman test. This conclusion is based on the fact that, despite
compound 3 is the best inhibitor of EeAChE, its action for reactiva-
tion of the enzyme inhibited by paraoxon is certainly inferior to
2-PAM as shown by NMR, which is a result completely different
from the one obtained by the Ellman test.
There exists several methods for enzyme kinetics and inhibition
studies, mainly by spectrophotometry and radiometric assays, for
example, UV–Visible spectroscopy, mass spectrometry, ﬂuores-
cence, temperature and pressure jump methods.71 Methods that
led to certain problems could be improved by some modiﬁcations,
for example, the Ellman test with changes on the values of kmax
sometimes leads to better results.72 However, NMR is especially
important for these studies because is a very effective method to
determine and distinguish the structure, conformation and con-
centration of enzyme substrates, products and inhibitors. Even
more, besides the enzyme kinetic and inhibition studies, NMR pro-
vides much other information, like molecular diffusion coefﬁcients,
relaxation times and inter-atomic distances, which are important
to study the interaction of these compounds with their bio-molec-
ular targets.57,73
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